Elevance Health, Inc. filings document formal disclosures for a health benefits and healthcare services company, including Form 8-K reports of quarterly and annual results, earnings guidance, benefit expense ratio updates, and Regulation FD communications. The filings also cover leadership changes, Carelon oversight, board appointments, committee assignments, and executive compensation matters reported through proxy materials.
Its regulatory documents include risk and operating disclosures tied to Health Benefits, Carelon, pharmacy and diversified healthcare services, provider contracting, product mix, government program funding, CMS Star Ratings, litigation, investigations, audits and professional-liability exposure. Recent 8-K disclosures also address CMS oversight of the company's Medicare Advantage-Prescription Drug plans.
Craig Ryan R, EVP & Chief HR Officer of Elevance Health, Inc. (ELV), reported equity awards and an option grant on 09/02/2025. He was awarded 970 restricted share units (RSUs) with a $0 purchase price and now beneficially owns 5,353 shares. He also received an employee stock option with an exercise price of $322.33 for 3,690 shares, exercisable in three annual installments beginning 09/02/2026 and expiring 09/02/2035, leaving 3,690 underlying shares from the option. The RSUs vest in annual installments of 323, 323, and 324 shares on 9/2/2026, 9/2/2027 and 9/2/2028 respectively.
Elevance Health management expects to reaffirm full-year 2025 shareholders' earnings guidance of approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding those items, the Company expects adjusted shareholders' earnings of approximately $30.00 per diluted share.
The company also plans to reaffirm a full-year 2025 benefit expense ratio guidance of approximately 90.0%. Management cautions these expectations reflect current views of market, operational, regulatory and claim-cost assumptions and may change, and the filing includes standard forward-looking statement disclosures.
Susan D. DeVore, a director of Elevance Health, reported purchases of common stock totaling 1,200 shares on 08/19/2025 at a weighted average price of $312.15 per share. After these purchases she beneficially owned 3,502 shares directly. The filing specifies the purchases were executed in multiple trades at prices between $312.06 and $312.19, and the weighted average price is disclosed. The Form 4 was signed by an attorney-in-fact for the reporting person.